The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with atomoxetine may have a decreased, but not absent, risk for treatment related side effects as compared to patients with two no function alleles. Other genetic and clinical factors may also influence response to atomoxetine.